Company veteran Thomas Grein slated to retire
Lilly said Wednesday that Smiley, currently senior vice president of finance, controller and chief financial officer for Lilly Research Laboratories, assumes his new post on Oct. 1. He replaces Thomas Grein, who will retire in September after a 41-year career at the company.
Smiley, who has been with the company 21 years, will report to Derica Rice, executive vice president of global services and chief financial officer at Eli Lilly.
“Josh’s knowledge and skill helped to place Lilly in a position of strength,” Rice stated. “Josh is a strong analytical and strategic thinker who excels at distilling complex business matters into clear thoughts and actions.”
Grein has been “a steadfast pillar of leadership in our financial organization,” added Rice. “With Tom’s guidance, we maintained a strong balance sheet and cash flow that enabled us to make acquisitions and sustain our dividend commitment to Lilly shareholders.”
With the promotion of Smiley, Lilly has named 15-year company veteran Anat Ashkenazi as vice president of finance and chief financial officer for Lilly Manufacturing, Global Quality and Lilly Diabetes to take over Smiley’s role. She currently serves as senior director of finance and chief financial officer for Lilly Oncology.
“Her exposure to many parts of our organization — including R&D, manufacturing and commercial — combined with her learning agility, energy and commitment, position Anat well for her new role,” commented Rice.